Drug intelligence / Profile preview

fluocinolone acetonide + neomycin sulfate + polymyxin B sulfate

Development stage
Unknown
Lead developer
Euro Med Laboratories
Modality
Peptides, Small Molecules
Administration
Otic
01

Overview

**Synalar Otic** is a fixed-dose otic anti-inflammatory and antibacterial combination containing fluocinolone acetonide, neomycin sulfate, and polymyxin B sulfate. Fluocinolone acetonide is a synthetic corticosteroid that activates glucocorticoid receptor signaling to reduce local inflammation, pruritus, and edema; neomycin inhibits bacterial protein synthesis through the bacterial 30S ribosomal subunit; and polymyxin B disrupts susceptible Gram-negative bacterial outer membranes through interaction with lipopolysaccharide. The product is used for otitis externa and steroid-responsive inflammatory conditions of the ear when bacterial infection is present or suspected. Euro-Med Laboratories lists Synalar Ortic among its commercial products, while public drug references identify Synalar Otic as the fluocinolone acetonide, neomycin sulfate, and polymyxin B sulfate otic combination. ([euromedlab.net](https://www.euromedlab.net/))

Brand names
Synalar Otic
Other names
Synalar Ortic
02

Targets

GR (Glucocorticoid receptor)Bacterial RibosomeLipid A

Beyond the preview

Go deeper on fluocinolone acetonide + neomycin sulfate + polymyxin B sulfate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluocinolone acetonide + neomycin sulfate + polymyxin B sulfate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call